Figure 6
Peripheral blood-derived CD161+ T cells from Crohn’s (CD) patients are not more responsive to tumor necrosis factor (TNF)-like cytokine 1A (TL1A) and do not have elevated serum TL1A levels. (a, b) Peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood of healthy volunteers (HVs) or CD patients (n=3 each) and treated with interleukin (IL)12 and IL18 plus TL1A or TNFα, similar to Figure 4. (a) The percentage of CD3+CD56−CD161+ T cells were analyzed by flow cytometry. (b) Interferon (IFN)γ mean fluorescence intensity (MFI) was measured after 24 h in CD patients. Patient characteristics are listed in Table 1. (c, d) Serum samples were collected from control, ulcerative colitis (UC), and CD patients are analyzed for the expression of (c) TL1A (c) or (d) TNFα. Each patient or HV CD161+ sample was run in triplicate and then averaged. For serum samples, each patient serum was analyzed in duplicate and averaged. NT, not receiving any treatment.
